| pubmed-article:18026989 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18026989 | lifeskim:mentions | umls-concept:C0035820 | lld:lifeskim |
| pubmed-article:18026989 | lifeskim:mentions | umls-concept:C0278678 | lld:lifeskim |
| pubmed-article:18026989 | lifeskim:mentions | umls-concept:C0007578 | lld:lifeskim |
| pubmed-article:18026989 | lifeskim:mentions | umls-concept:C1332712 | lld:lifeskim |
| pubmed-article:18026989 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:18026989 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:18026989 | lifeskim:mentions | umls-concept:C0220901 | lld:lifeskim |
| pubmed-article:18026989 | lifeskim:mentions | umls-concept:C0868928 | lld:lifeskim |
| pubmed-article:18026989 | lifeskim:mentions | umls-concept:C0205225 | lld:lifeskim |
| pubmed-article:18026989 | lifeskim:mentions | umls-concept:C2911684 | lld:lifeskim |
| pubmed-article:18026989 | lifeskim:mentions | umls-concept:C0185117 | lld:lifeskim |
| pubmed-article:18026989 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:18026989 | pubmed:dateCreated | 2007-12-21 | lld:pubmed |
| pubmed-article:18026989 | pubmed:abstractText | Possible prognostic utility of CD44 in renal cell carcinoma (RCC) prompted a comparison of its expression in primary and metastatic RCC. A total of 164 paraffin-embedded tissues of primary RCC and metastatic RCCs from 125 patients were immunostained with CD44 (standard form) antibody. It consisted of 86 primary RCCs (50 with subsequent metastasis [MET+] and 36 with no known metastasis [MET-]) during follow up and 78 metastatic RCCs (39 metastatic RCCs only and 39 with matched RCC primary from RCC MET + category). Immunoreactivity for CD44 was scored semiquantitatively as 0, 1, or 2 (0, <5%; 1, 5-50%; 2, > or =50%). Expression of CD44 was significantly higher in metastatic RCCs compared to primary RCCs (p = 0.036). CD44 immunoreactivity in the primary RCC (MET- and MET+) correlated with progression-free survival (p = 0.027). In metastatic RCCs, CD44 immunoreactivity also correlated with survival after detection of first metastasis (p = 0.011). In multivariate analysis, stage (p = 0.0001) and CD44 immunoreactivity (p = 0.03) in primary RCC were independent predictors of progression-free survival. Our study suggests that CD44 status in RCC provides useful prognostic information both in primary and metastatic RCCs and may have applicability in stratifying patients for therapeutic decisions. | lld:pubmed |
| pubmed-article:18026989 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18026989 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18026989 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18026989 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18026989 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18026989 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18026989 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18026989 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:18026989 | pubmed:issn | 0945-6317 | lld:pubmed |
| pubmed-article:18026989 | pubmed:author | pubmed-author:AminMahul BMB | lld:pubmed |
| pubmed-article:18026989 | pubmed:author | pubmed-author:PanerGladell... | lld:pubmed |
| pubmed-article:18026989 | pubmed:author | pubmed-author:YoungAndrew... | lld:pubmed |
| pubmed-article:18026989 | pubmed:author | pubmed-author:LimSo DugSD | lld:pubmed |
| pubmed-article:18026989 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18026989 | pubmed:volume | 452 | lld:pubmed |
| pubmed-article:18026989 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18026989 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18026989 | pubmed:pagination | 49-55 | lld:pubmed |
| pubmed-article:18026989 | pubmed:meshHeading | pubmed-meshheading:18026989... | lld:pubmed |
| pubmed-article:18026989 | pubmed:meshHeading | pubmed-meshheading:18026989... | lld:pubmed |
| pubmed-article:18026989 | pubmed:meshHeading | pubmed-meshheading:18026989... | lld:pubmed |
| pubmed-article:18026989 | pubmed:meshHeading | pubmed-meshheading:18026989... | lld:pubmed |
| pubmed-article:18026989 | pubmed:meshHeading | pubmed-meshheading:18026989... | lld:pubmed |
| pubmed-article:18026989 | pubmed:meshHeading | pubmed-meshheading:18026989... | lld:pubmed |
| pubmed-article:18026989 | pubmed:meshHeading | pubmed-meshheading:18026989... | lld:pubmed |
| pubmed-article:18026989 | pubmed:meshHeading | pubmed-meshheading:18026989... | lld:pubmed |
| pubmed-article:18026989 | pubmed:meshHeading | pubmed-meshheading:18026989... | lld:pubmed |
| pubmed-article:18026989 | pubmed:meshHeading | pubmed-meshheading:18026989... | lld:pubmed |
| pubmed-article:18026989 | pubmed:meshHeading | pubmed-meshheading:18026989... | lld:pubmed |
| pubmed-article:18026989 | pubmed:meshHeading | pubmed-meshheading:18026989... | lld:pubmed |
| pubmed-article:18026989 | pubmed:meshHeading | pubmed-meshheading:18026989... | lld:pubmed |
| pubmed-article:18026989 | pubmed:meshHeading | pubmed-meshheading:18026989... | lld:pubmed |
| pubmed-article:18026989 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18026989 | pubmed:articleTitle | Prognostic role of CD44 cell adhesion molecule expression in primary and metastatic renal cell carcinoma: a clinicopathologic study of 125 cases. | lld:pubmed |
| pubmed-article:18026989 | pubmed:affiliation | Department of Pathology, Konkuk University School of Medicine, Gwangjin-Gu, Seoul, Republic of Korea. | lld:pubmed |
| pubmed-article:18026989 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18026989 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:18026989 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| entrez-gene:25406 | entrezgene:pubmed | pubmed-article:18026989 | lld:entrezgene |
